Welcome to our dedicated page for Avidity Biosciences news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Avidity Biosciences stock.
Avidity Biosciences, Inc. (Nasdaq: RNA) is a pioneering biopharmaceutical company dedicated to revolutionizing RNA therapeutics with its proprietary Antibody Oligonucleotide Conjugates (AOCs™). Their innovative approach merges the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, enabling targeted treatment of diseases that were previously unreachable with existing RNA therapies. They are at the forefront of developing therapies for serious genetic conditions, predominantly focusing on rare muscle diseases.
Avidity's leading clinical programs include:
- AOC 1001 (Del-desiran): Targeting Myotonic Dystrophy Type 1 (DM1), a disease with no approved therapies. Del-desiran has shown promising long-term data from the MARINA-OLE™ trial, demonstrating reversal of disease progression in patients. The global Phase 3 HARBOR™ trial is set to begin, with video hand opening time (vHOT) as the primary endpoint.
- AOC 1044: Aimed at Duchenne Muscular Dystrophy (DMD) with mutations amenable to exon 44 skipping. Recently, it achieved Rare Pediatric Disease and Orphan Drug designations from the FDA and EMA. Positive preliminary data has been reported from the Phase 1/2 EXPLORE44™ clinical trial.
- AOC 1020: Focused on Facioscapulohumeral Muscular Dystrophy (FSHD). Clinical data from the Phase 1/2 FORTITUDE™ trial is expected soon.
Avidity is also advancing its pipeline to include cardiology and immunology programs, aiming to target a broader range of diseases. The company has garnered support and collaborations with top-tier investors and strategic partners, enhancing its capability to deliver groundbreaking treatments.
With headquarters in San Diego, CA, Avidity Biosciences is committed to transforming lives through innovative RNA therapeutics. For more information, visit www.aviditybiosciences.com.
Avidity Biosciences (Nasdaq: RNA) reported its Q1 2021 financial results, highlighting significant progress in its AOC platform, particularly AOC 1001 for myotonic dystrophy type 1 (DM1). The company has over $300 million cash reserves, enabling continued investment in its pipeline. Collaboration revenue rose to $2.7 million, driven by a partnership with Eli Lilly. R&D expenses surged to $20.7 million due to advancing clinical programs. G&A expenses also increased to $5.9 million, reflecting higher personnel and professional costs.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced a virtual investor and analyst event on May 19, 2021, from 8:00 a.m. to 10:00 a.m. PT. The event will showcase the company's innovative AOC platform and include a panel discussion with experts Drs. Phillip D. Zamore, Steven F. Dowdy, and Avidity's Chief Scientific Officer, Art Levin. Attendees will have the opportunity to engage in a Q&A session. A live video webcast of the event will be available on Avidity's website, along with a replay post-event.
Avidity Biosciences (Nasdaq: RNA) announced the presentation of preclinical data for its lead candidate, AOC 1001, targeting myotonic dystrophy type 1 (DM1), at the AAN 2021 Virtual Annual Meeting from April 17-22, 2021. Chosen as one of 11 highlighted abstracts, the data demonstrate a 75% reduction in DMPK mRNA levels post-treatment, indicating AOC 1001's potential as the first therapy for DM1. The oral presentation is scheduled for April 18, 2021. Avidity aims to initiate a Phase 1/2 study for AOC 1001 in late 2021.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced its participation in multiple virtual investor conferences. Key events include the Guggenheim Healthcare Talks on April 1, where a panel on Duchenne Muscular Dystrophy will feature Avidity's Chief Scientific Officer, Arthur Levin, and prominent industry leaders. Additionally, Avidity will engage in investor meetings at the 2021 Virtual Wells Fargo Biotech Corporate Access Day on April 6, followed by a webcast presentation at the 20th Annual Needham Virtual Healthcare Conference on April 12. Live webcasts and replays will be available on Avidity's website.
Avidity Biosciences (Nasdaq: RNA) reported its financial results for Q4 and the full year 2020, showcasing significant advancements in its AOC pipeline. The company has $328 million in cash and plans to initiate a Phase 1/2 study of AOC 1001 for myotonic dystrophy type 1 (DM1) in late 2021. Collaboration revenue increased to $6.8 million for 2020, up from $2.3 million in 2019. R&D expenses surged to $37.6 million, driven by progress on AOC 1001. General and administrative expenses also rose to $13.5 million as the company scales operations as a public entity.
Avidity Biosciences (Nasdaq: RNA) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 2:00 PM PST. CEO Sarah Boyce and CSO Art Levin will engage in a virtual fireside chat. A live webcast will be available on the company’s website, with a replay archived for 90 days. Avidity is pioneering Antibody Oligonucleotide Conjugates (AOCs™) to treat serious diseases, including myotonic dystrophy type 1. For more details, visit www.aviditybiosciences.com.
Avidity Biosciences (RNA) announced the appointment of W. Michael Flanagan, Ph.D., as Chief Technical Officer on January 21, 2021. Dr. Flanagan will guide the development strategy for Avidity's Antibody Oligonucleotide Conjugates (AOCs™) as they progress to clinical stages. With extensive experience in RNA therapeutics and monoclonal antibodies, Dr. Flanagan previously held leadership roles at Genentech and other notable companies. This leadership change aims to enhance Avidity’s pipeline and strengthen its innovative AOC technology, targeting serious diseases like myotonic dystrophy and Duchenne muscular dystrophy.
Avidity Biosciences announced the appointment of Tamar Thompson and Jean Kim to its Board of Directors, replacing Todd Brady and Michael Martin. Thompson brings expertise in health policy and market access, while Kim has over 20 years of experience in healthcare investment. The company aims to advance its Antibody Oligonucleotide Conjugates (AOCs) pipeline, with hopes of transforming treatments for serious diseases. Troy Wilson transitions to Chairman, highlighting leadership changes at a pivotal time for Avidity’s development.
Avidity Biosciences (RNA) announced significant pipeline updates and a new research collaboration with MyoKardia on January 8, 2021. Notably, AOC 1001 is set to enter Phase 1/2 studies for myotonic dystrophy type 1, marking a key milestone in the company’s development efforts. Also in 2021, Avidity will advance AOC FSHD into IND-enabling studies and expand its Duchenne muscular dystrophy programs targeting multiple mutations. This collaboration aims to explore AOCs in cardiac applications, furthering Avidity's strategic objectives.
Avidity Biosciences (Nasdaq: RNA) announced that CEO Sarah Boyce will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 12:40 PM PST. The event will be held virtually. A live webcast can be accessed on the company's website, with a replay available for 30 days.
Avidity is focused on developing Antibody Oligonucleotide Conjugates (AOCs™), targeting serious diseases through its proprietary platform. Its lead candidate, AOC 1001, aims to treat myotonic dystrophy type 1, along with programs for various muscle diseases.
FAQ
What is the current stock price of Avidity Biosciences (RNA)?
What is the market cap of Avidity Biosciences (RNA)?
What is Avidity Biosciences, Inc.?
What are Antibody Oligonucleotide Conjugates (AOCs™)?
What is AOC 1001 (Del-desiran)?
What are the key clinical programs of Avidity Biosciences?
What designations has AOC 1044 received?
What is the significance of the MARINA-OLE™ trial?
What other areas is Avidity Biosciences expanding into?
Where is Avidity Biosciences headquartered?
How is Avidity Biosciences funded?
How can I learn more about Avidity Biosciences?
